CRISPR-Based Therapy for Hereditary Angioedema

Abstract excerpt

BACKGROUND: ). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. METHODS: In this phase 2 portion of a phase 1-2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo. The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to Complement system in diseases
• Share to Hemophilia Treatment and Research